Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study

Table 1 Clinical characteristics of the included patients at the time of diagnosis of extensive-stage small cell lung cancer (ES-SCLC)

Variable		n/N (%)
Age, years	< 65	231/548 (42.2)
	65–75	211/548 (38.5)
	> 75	106/548 (19.3)
Eastern Cooperative Oncology Group (ECOG) performance status	0	103/546 (18.9)
	1	280/546 (51.3)
	2	112/546 (20.5)
	> 2	51/546 (9.3)
Presence of paraneoplastic syndromes		51/545 (9.4)
Presence of at least one severe comorbidity†		149/545 (27.3)
Presence of metastasis	None	28/537 (5.2)
	Symptomatic brain metastasis only	20/537 (3.7)
	Asymptomatic brain metastasis only	13/537 (2.4)
	Multi-organ metastases including symptomatic brain metastasis	252/537 (46.9)
	Multi-organ metastases including asymptomatic brain metastasis	224/537 (41.7)
Corticosteroid use before initiation of first-line therapy		117/524 (22.3)

†Included severe comorbidities were: chronic obstructive pulmonary disease (COPD) classified according to the Global Initiative for Obstructive Lung Disease (GOLD) as GOLD 3 (severe) or GOLD 4 (very severe); interstitial lung disease with a transfer factor for carbon monoxide (TLCO) > 70% or 50–70%; congestive heart failure; complicated diabetes; moderate to severe renal impairment; moderate to severe hepatic impairment; hemopathy; use of immunosuppressant medications
n refers to the number of evaluated patients for each parameter, and N refers to the total number of patients with available information

ISSN: 1471-2407